Business Wire

NTHU

2.10.2021 07:02:10 CEST | Business Wire | Press release

Share
Ushering in a New Era of Medical Education at NTHU

National Tsing Hua University’s plan to establish a post-baccalaureate program in medicine has been approved at a recent cross-ministerial meeting held at the Ministry of Education. The school’s recruitment and admission application process will begin by the end of 2021, and the first class of government-sponsored students will be enrolled in September 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211001005043/en/

NTHU President Hocheng Hong said that NTHU already has a strong foundation in cross-disciplinary research in medical science, including big data analysis, application of artificial intelligence (AI), bioengineering, material science, and nuclear medicine, by which the school is well-positioned to train physicians specializing in more than one expertise. As such, this new program represents a quantum jump in medical education in Taiwan.

President Hocheng said that NTHU already has sufficient number of faculty members, funding, and infrastructure for the new program. In addition to the existing 180 faculty members teaching related courses, the program has recently recruited an additional 71 full-time faculty members, and 87 physician scientists from leading medical centers throughout Taiwan as adjunct faculty members. Moreover, the provisional office of this program has raised NT$2 billion for medical education. An ongoing plan for establishing a state-of-the-art teaching hospital and medical complex in the Taoyuan Aerotropolis next to the Taoyuan International Airport is currently being reviewed by the Ministry of Health and Welfare.

The post-baccalaureate program in medicine is a four-year program, open for graduates from all disciplines. The government-sponsored students will be required to serve in a public healthcare facility for six years. They will have an opportunity to undertake an additional two years of advanced training in a medical center.

NTHU will draw on its extensive experience in student recruitment to admit only those applicants who meet the stringent admission qualifications, the innovative student selection process could open a new path for medical education in Taiwan.

The post-baccalaureate program in medicine will be part of the future College of Life Sciences and Medicine (currently the College of Life Science). Dean of the College of Life Science, Kao Ruey-Ho, former Superintendent of Tzu Chi Medical Center, said that applicants who apply directly to NTHU will be evaluated based on test scores, transcripts, and interviews, to select students who have demonstrated academic excellence, as well as a passion for medicine and public welfare.

Government-sponsored students in the program will take several courses designed to prepare them for practicing in a rural area, such as Community Medicine Practicum, and make good use of AI diagnosis and telemedicine technology; they will also attend seminars on altruism and dedication to public health, which will be taught by laureates of the Medical Contribution Award.

Social Media:

https://www.facebook.com/nthu.tw

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye